Shattuck Labs, Inc. Shareholders' Equity
Shattuck Labs, Inc. (STTK) had Shareholders' Equity of $211.14 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $211.14M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $95.83M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $82.39M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $93.24M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $211.14M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $95.83M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $82.39M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $93.24M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $57.02M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $67.59M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $79.63M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $96.58M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $110.62M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $128.81M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $144.71M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $112.78M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $138.46M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $157.65M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $176.16M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $199.42M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $222.53M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $248.94M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $271.79M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $261.17M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $277.09M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | $298.66M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $309.86M 10-K · filed 2023-02-23 | |
| 2020-09-30 | -$58.36M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$47.03M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | -$40.86M 10-Q · filed 2021-11-09 | -$41.09M 10-Q · filed 2020-11-13 |
| 2019-12-31 | -$34.55M 10-K · filed 2022-03-15 | |
| 2019-09-30 | -$27.28M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$20.15M 10-Q · filed 2020-11-13 | |
| 2019-03-31 | -$14.42M 10-Q · filed 2020-11-13 | |
| 2018-12-31 | -$11.08M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |